SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Mike Grey will be moderating a panel discussion on strategies for CNS drug and device development at the Neurotech Investing and Partnering Conference in San Francisco, CA.
News | 05. 10. 2011
